Stay updated on IMGN632 in BPDCN Clinical Trial

Sign up to get notified when there's something new on the IMGN632 in BPDCN Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IMGN632 in BPDCN Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:39:46.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or revision in the study details related to the open-label, multi-center Phase 1/2 study of IMGN632 in patients with CD123+ disease, focusing on determining the MTD and assessing safety, tolerability, PK, immunogenicity, and anti-leukemia activity.
    Difference
    0.1%
    Check dated 2024-06-06T14:44:00.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying disease characteristics and prior treatments required for inclusion. Previously, this section had no information provided.
    Difference
    30%
    Check dated 2024-05-22T21:31:06.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:33:11.000Z thumbnail image

Stay in the know with updates to IMGN632 in BPDCN Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IMGN632 in BPDCN Clinical Trial page.